Ozempic vs Krispy Kreme: Wall Street firm bets weight-loss drugs won’t beat doughnut sales - Fox Business
foxbusiness.comSubmitted by foxbusiness4472 in business
Wall Street firm Truist Securities is betting that consumers will still buy Krispy Kreme doughnuts amid the surge in weight-loss drugs like Novo Nordisk's Ozempic.